Compare Lupin with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs CIPLA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN CIPLA LUPIN/
CIPLA
 
P/E (TTM) x 41.5 34.0 122.1% View Chart
P/BV x 3.8 4.8 79.4% View Chart
Dividend Yield % 0.6 0.4 133.4%  

Financials

 LUPIN   CIPLA
EQUITY SHARE DATA
    LUPIN
Mar-20
CIPLA
Mar-20
LUPIN/
CIPLA
5-Yr Chart
Click to enlarge
High Rs882586 150.7%   
Low Rs505357 141.5%   
Sales per share (Unadj.) Rs339.4207.0 163.9%  
Earnings per share (Unadj.) Rs-5.918.6 -32.0%  
Cash flow per share (Unadj.) Rs15.533.2 46.6%  
Dividends per share (Unadj.) Rs6.004.00 150.0%  
Dividend yield (eoy) %0.90.8 101.9%  
Book value per share (Unadj.) Rs276.7195.5 141.6%  
Shares outstanding (eoy) m453.00806.35 56.2%   
Bonus/Rights/Conversions ESOPESOS-  
Price / Sales ratio x2.02.3 89.8%   
Avg P/E ratio x-116.625.3 -460.4%  
P/CF ratio (eoy) x44.814.2 315.6%  
Price / Book Value ratio x2.52.4 104.0%  
Dividend payout %-100.921.5 -469.1%   
Avg Mkt Cap Rs m314,201379,912 82.7%   
No. of employees `00018.325.8 70.8%   
Total wages/salary Rs m29,86830,270 98.7%   
Avg. sales/employee Rs Th8,400.66,459.6 130.0%   
Avg. wages/employee Rs Th1,632.01,171.2 139.3%   
Avg. net profit/employee Rs Th-147.2580.2 -25.4%   
INCOME DATA
Net Sales Rs m153,748166,949 92.1%  
Other income Rs m4,8383,442 140.5%   
Total revenues Rs m158,585170,391 93.1%   
Gross profit Rs m24,84932,060 77.5%  
Depreciation Rs m9,70211,747 82.6%   
Interest Rs m3,6301,974 183.9%   
Profit before tax Rs m16,35521,782 75.1%   
Minority Interest Rs m4-475 -0.8%   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5716,312 183.3%   
Profit after tax Rs m-2,69414,995 -18.0%  
Gross profit margin %16.219.2 84.2%  
Effective tax rate %70.829.0 244.2%   
Net profit margin %-1.89.0 -19.5%  
BALANCE SHEET DATA
Current assets Rs m154,132117,038 131.7%   
Current liabilities Rs m92,25243,931 210.0%   
Net working cap to sales %40.243.8 91.9%  
Current ratio x1.72.7 62.7%  
Inventory Days Days8296 85.7%  
Debtors Days Days12985 152.0%  
Net fixed assets Rs m89,082107,424 82.9%   
Share capital Rs m9061,613 56.2%   
"Free" reserves Rs m124,461156,018 79.8%   
Net worth Rs m125,367157,630 79.5%   
Long term debt Rs m17,93323,693 75.7%   
Total assets Rs m249,839236,626 105.6%  
Interest coverage x5.512.0 45.7%   
Debt to equity ratio x0.10.2 95.2%  
Sales to assets ratio x0.60.7 87.2%   
Return on assets %0.47.2 5.2%  
Return on equity %-2.19.5 -22.6%  
Return on capital %8.712.8 68.0%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45056,036 91.8%   
Fx outflow Rs m19,4706,764 287.8%   
Net fx Rs m31,98049,272 64.9%   
CASH FLOW
From Operations Rs m14,68830,685 47.9%  
From Investments Rs m11,0701,040 1,064.0%  
From Financial Activity Rs m-8,906-29,488 30.2%  
Net Cashflow Rs m16,8532,340 720.1%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Apr 16, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS